Published in Can J Vet Res on January 01, 1998
Rapid evolution of virulence and drug resistance in the emerging zoonotic pathogen Streptococcus suis. PLoS One (2009) 2.38
SalK/SalR, a two-component signal transduction system, is essential for full virulence of highly invasive Streptococcus suis serotype 2. PLoS One (2008) 1.64
Agents of the "suis-ide diseases" of swine: Actinobacillus suis, Haemophilus parasuis, and Streptococcus suis. Can J Vet Res (1999) 1.63
Relatedness of Streptococcus suis serotype 2 isolates from different geographic origins as evaluated by molecular fingerprinting and phenotyping. J Clin Microbiol (1999) 1.50
Relatedness of Streptococcus suis isolates of various serotypes and clinical backgrounds as evaluated by macrorestriction analysis and expression of potential virulence traits. J Clin Microbiol (2001) 1.48
Distribution and genetic diversity of suilysin in Streptococcus suis isolated from different diseases of pigs and characterization of the genetic basis of suilysin absence. Infect Immun (2001) 1.35
Heat-killed Streptococcus suis capsular type 2 strains stimulate tumor necrosis factor alpha and interleukin-6 production by murine macrophages. Infect Immun (1999) 1.32
Slaughterhouse pigs are a major reservoir of Streptococcus suis serotype 2 capable of causing human infection in southern Vietnam. PLoS One (2011) 1.26
Dilemma of virulence of Streptococcus suis: Canadian isolate 89-1591 characterized as a virulent strain using a standardized experimental model in pigs. Can J Vet Res (2005) 1.22
Invasion of porcine brain microvascular endothelial cells by Streptococcus suis serotype 2. Infect Immun (2004) 1.22
Streptococcus suis in humans, Thailand. Emerg Infect Dis (2008) 1.21
Streptococcus suis infection: an emerging/reemerging challenge of bacterial infectious diseases? Virulence (2014) 1.17
Genetic diversity of Streptococcus suis strains isolated from pigs and humans as revealed by pulsed-field gel electrophoresis. J Clin Microbiol (2002) 1.12
Streptococcus suis interactions with the murine macrophage cell line J774: adhesion and cytotoxicity. Infect Immun (2002) 1.11
Identification of a surface protein of Streptococcus suis and evaluation of its immunogenic and protective capacity in pigs. Infect Immun (2006) 1.10
Experimental infection of specific pathogen free piglets with French strains of Streptococcus suis capsular type 2. Can J Vet Res (2001) 1.06
Immunization with recombinant Sao protein confers protection against Streptococcus suis infection. Clin Vaccine Immunol (2007) 1.05
Prevalence of Streptococcus suis genotypes in wild boars of Northwestern Germany. Appl Environ Microbiol (2006) 0.95
Investigation of a novel DNase of Streptococcus suis serotype 2. Infect Immun (2004) 0.91
Up-regulation of ICAM-1, CD11a/CD18 and CD11c/CD18 on human THP-1 monocytes stimulated by Streptococcus suis serotype 2. Clin Exp Immunol (2003) 0.90
Clonal distribution of an atypical MRP+, EF*, and suilysin+ phenotype of virulent Streptococcus suis serotype 2 strains in Brazil. Can J Vet Res (2003) 0.90
Identification of an inducible bacteriophage in a virulent strain of Streptococcus suis serotype 2. Infect Immun (2003) 0.86
Characterization of Streptococcus suis isolates from slaughter swine. Curr Microbiol (2012) 0.86
Evidence for lateral transfer of the Suilysin gene region of Streptococcus suis. J Bacteriol (2002) 0.83
Correlation between PFGE Groups and mrp/epf/sly Genotypes of Human Streptococcus suis Serotype 2 in Northern Thailand. J Pathog (2014) 0.82
Antibody response to an autogenous vaccine and serologic profile for Streptococcus suis capsular type 1/2. Can J Vet Res (2002) 0.82
Genetic diversity of Streptococcus suis serotypes 2 and 1/2 isolates recovered from carrier pigs in closed herds. Can J Vet Res (2002) 0.81
Different foreign genes incidentally integrated into the same locus of the Streptococcus suis genome. J Bacteriol (2005) 0.80
Identification and experimental verification of protective antigens against Streptococcus suis serotype 2 based on genome sequence analysis. Curr Microbiol (2008) 0.78
Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine. Infect Immun (2016) 0.78
Suilysin Stimulates the Release of Heparin Binding Protein from Neutrophils and Increases Vascular Permeability in Mice. Front Microbiol (2016) 0.77
Genetic diversity of Streptococcus suis serotype 2 isolated from pigs in Brazil. Can J Vet Res (2016) 0.77
Identification of the gene encoding a 38-kilodalton immunogenic and protective antigen of Streptococcus suis. Clin Diagn Lab Immunol (2005) 0.75
Meningitis caused by Streptococcus suis in humans. Rev Infect Dis (1988) 5.84
An update on Streptococcus suis identification. J Vet Diagn Invest (1990) 3.43
Identification of two proteins associated with virulence of Streptococcus suis type 2. Infect Immun (1991) 3.12
Distribution of Streptococcus suis capsular types in Quebec and western Canada. Can Vet J (1992) 2.83
A case of human endocarditis due to Streptococcus suis in North America. Rev Infect Dis (1992) 2.63
Differences in virulence between two strains of Streptococcus suis type II after experimentally induced infection of newborn germ-free pigs. Am J Vet Res (1989) 2.56
Virulence of Streptococcus suis type 2 strains in newborn germfree pigs depends on phenotype. Infect Immun (1992) 2.52
Identification, purification, and characterization of a thiol-activated hemolysin (suilysin) of Streptococcus suis. Infect Immun (1994) 2.24
Description of six new capsular types (29-34) of Streptococcus suis. J Vet Diagn Invest (1995) 2.16
Characterization of Streptococcus suis capsular type 2 haemolysin. Microbiology (1995) 1.83
Discrimination of virulent and avirulent Streptococcus suis capsular type 2 isolates from different geographical origins. Infect Immun (1995) 1.68
Molecular analysis of isolates of Streptococcus suis capsular type 2 by restriction-endonuclease-digested DNA separated on SDS-PAGE and by hybridization with an rDNA probe. J Gen Microbiol (1992) 1.56
Production and characterization of two Streptococcus suis capsular type 2 mutants. Vet Microbiol (1992) 1.54
Clonal analysis and virulence of Australian isolates of Streptococcus suis type 2. Epidemiol Infect (1994) 1.23
Discrimination between virulent and nonvirulent Streptococcus suis type 2 strains by enzyme-linked immunosorbent assay. Vet Microbiol (1993) 1.16
Partial characterization of Streptococcus suis type 2 hemolysin. J Clin Microbiol (1994) 1.15
Protective effect of sera raised against different fractions of Streptococcus suis type 2. J Comp Pathol (1990) 1.14
Production of suilysin, the thiol-activated haemolysin of Streptococcus suis, by field isolates from diseased pigs. Vet Rec (1995) 1.14
Antimicrobial resistance patterns and plasmid profiles of Streptococcus suis isolates. J Vet Diagn Invest (1992) 1.03
Prevalence of various phenotypes of Streptococcus suis isolated from swine in the U.S.A. based on the presence of muraminidase-released protein and extracellular factor. Can J Vet Res (1996) 0.98
The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. N Engl J Med (1978) 15.13
General practitioner's perceptions of the route to evidence based medicine: a questionnaire survey. BMJ (1998) 13.39
Antibodies to ribosomes in chronic active hepatitis. Gastroenterology (1979) 12.78
DNA: an extensible molecule. Science (1996) 8.19
Randomized versus historical controls for clinical trials. Am J Med (1982) 7.53
Performance indicators for primary care groups: an evidence based approach. BMJ (1998) 6.97
A method for assessing the quality of a randomized control trial. Control Clin Trials (1981) 6.63
Microbial surfaces in relation to pathogenicity. Bacteriol Rev (1977) 5.79
Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med (2000) 5.68
Bias in treatment assignment in controlled clinical trials. N Engl J Med (1983) 4.78
Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial. BMJ (2010) 4.53
Publication bias and clinical trials. Control Clin Trials (1987) 4.34
Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest (1996) 3.74
MR imaging and T2 mapping of femoral cartilage: in vivo determination of the magic angle effect. AJR Am J Roentgenol (2001) 3.69
Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA (1995) 3.48
Giardia and Cryptosporidium join the 'Neglected Diseases Initiative'. Trends Parasitol (2006) 3.34
Future provision of out of hours primary medical care: a survey with two general practitioner research networks. BMJ (1996) 3.34
Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med (1977) 3.33
Paediatric intensive care transfers. Anaesthesia (2000) 3.32
Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med (1983) 3.04
Appropriateness of use of emergency ambulances. J Accid Emerg Med (1998) 3.02
Rate of regeneration of peripheral nerves in man. J Physiol (1943) 3.02
Transgene-mediated auxin overproduction in Arabidopsis: hypocotyl elongation phenotype and interactions with the hy6-1 hypocotyl elongation and axr1 auxin-resistant mutants. Plant Mol Biol (1995) 3.01
Infection and diabetes: the case for glucose control. Am J Med (1982) 2.90
Is perinatal mortality still a good indicator of perinatal care? Paediatr Perinat Epidemiol (1988) 2.87
Pathogenicity of influenza virus. Microbiol Rev (1980) 2.80
Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med (1997) 2.65
Effect of polymorphism of an MHC-linked transporter on the peptides assembled in a class I molecule. Nature (1992) 2.61
In vitro and in vivo modification of Neisseria gonorrhoeae lipooligosaccharide epitope structure by sialylation. J Exp Med (1990) 2.61
A survey of clinical trials of antibiotic prophylaxis in colon surgery: evidence against further use of no-treatment controls. N Engl J Med (1981) 2.59
Cancer in universal and left-sided ulcerative colitis: factors determining risk. Gastroenterology (1979) 2.48
Derivatives of 6-aminopenicillanic acid. XI. Alpha-amino-p-hydroxybenzylpenicillin. J Chem Soc Perkin 1 (1971) 2.39
Genetic engineering of harvest index in tobacco through overexpression of a phytochrome gene. Nat Biotechnol (1996) 2.36
Dipsticks and diagnostic algorithms in urinary tract infection: development and validation, randomised trial, economic analysis, observational cohort and qualitative study. Health Technol Assess (2009) 2.36
Overnight calls in primary care: randomised controlled trial of management using nurse telephone consultation. BMJ (1999) 2.32
Phytochrome and photomorphogenesis in plants. Nature (1970) 2.26
Paradoxical expansion of intracranial tuberculomas during chemotherapy. Lancet (1984) 2.19
Earthquake injuries related to housing in a guatemalan village. Science (1977) 2.18
Clinical governance in primary care groups: the feasibility of deriving evidence-based performance indicators. Qual Health Care (2000) 2.16
Description of six new capsular types (29-34) of Streptococcus suis. J Vet Diagn Invest (1995) 2.16
Preventive care for patients following myocardial infarction. The Wessex Research Network (WReN). Fam Pract (1997) 2.15
Biochemical challenge of microbial pathogenicity. Bacteriol Rev (1968) 2.14
Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene (2007) 2.14
The effect of high-sodium and low-sodium intakes on blood pressure and other related variables in human subjects with idiopathic hypertension. Am J Med (1978) 2.05
Women's views about management and cause of urinary tract infection: qualitative interview study. BMJ (2010) 2.03
Cost analysis of nurse telephone consultation in out of hours primary care: evidence from a randomised controlled trial. BMJ (2000) 1.99
Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet (1988) 1.98
Groin hernia repair in Scotland. Br J Surg (2000) 1.93
Food intolerance and the irritable bowel syndrome. Gut (1989) 1.88
Selection from gonococci grown in vitro of a colony type with some virulence properties of organisms adapted in vivo. J Gen Microbiol (1977) 1.85
Anthrax toxic complex. Fed Proc (1967) 1.84
Distribution of capsular types and production of muramidase-released protein (MRP) and extracellular factor (EF) of Streptococcus suis strains isolated from diseased pigs in seven European countries. Vet Microbiol (2000) 1.83
Characterization of Streptococcus suis capsular type 2 haemolysin. Microbiology (1995) 1.83
A comparison of cancer risk in Crohn's disease and ulcerative colitis. Cancer (1981) 1.83
Cytidine 5'-monophospho-N-acetyl neuraminic acid and a low molecular weight factor from human blood cells induce lipopolysaccharide alteration in gonococci when conferring resistance to killing by human serum. Microb Pathog (1988) 1.81
Sialylation of lipopolysaccharide and loss of absorption of bactericidal antibody during conversion of gonococci to serum resistance by cytidine 5'-monophospho-N-acetyl neuraminic acid. Microb Pathog (1989) 1.80
Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med (1992) 1.80
Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut (1979) 1.78
Streptococcus suis infections in pigs in the Netherlands (Part I). Vet Q (1985) 1.78
Challenges of cardiovascular risk assessment in the routine rheumatology outpatient setting: an observational study of 110 rheumatoid arthritis patients. Arthritis Care Res (Hoboken) (2013) 1.76
ICAP-1, a novel beta1 integrin cytoplasmic domain-associated protein, binds to a conserved and functionally important NPXY sequence motif of beta1 integrin. J Cell Biol (1997) 1.72
Cytidine 5'-monophospho-N-acetylneuraminic acid or a related compound is the low Mr factor from human red blood cells which induces gonococcal resistance to killing by human serum. J Gen Microbiol (1988) 1.72
1% or less: a community-based nutrition campaign. Public Health Rep (1998) 1.69
Discrimination of virulent and avirulent Streptococcus suis capsular type 2 isolates from different geographical origins. Infect Immun (1995) 1.68
Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet (1991) 1.67
Hydrogenated oils and fats: the presence of chemically-modified fatty acids in human adipose tissue. Am J Clin Nutr (1981) 1.65
Immunogenicity of peptides derived from a fibronectin-binding protein of S. aureus expressed on two different plant viruses. Vaccine (1999) 1.63
Reliability study of the European appropriateness evaluation protocol. Int J Qual Health Care (1999) 1.59
Comparative ocular pressure elevation by medrysone, fluorometholone, and dexamethasone phosphate. Arch Ophthalmol (1980) 1.59
Genome differences among varicella-zoster virus isolates. J Gen Virol (1983) 1.59
Factors affecting the induction of phenotypically determined serum resistance of Neisseria gonorrhoeae grown in media containing serum or its diffusible components. J Gen Microbiol (1981) 1.58
Penicillin neurotoxicity. Ann N Y Acad Sci (1967) 1.57
Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers. Q J Med (1989) 1.57
Sensitivity and specificity of clinical trials. Randomized v historical controls. Arch Intern Med (1983) 1.54
Subtyping of hepatitis-associated antigen (HB-Ag); simplified technique with counterelectrophoresis. J Immunol (1972) 1.54
Botulinum toxin A for hyperkinetic facial lines: results of a double-blind, placebo-controlled study. Plast Reconstr Surg (1994) 1.54
Prostaglandin synthesis by rheumatoid synovium and its stimulation by colchicine. Prostaglandins (1975) 1.53
Thirteen-year follow-up of deliberate self-harm, using linked data. Br J Psychiatry (1998) 1.50
Quantitative studies on the tissue localization of influenza virus in ferrets after intranasal and intravenous or intracardial inoculation. Br J Exp Pathol (1969) 1.50
Psychosis and aggression in Alzheimer's disease: the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry (2001) 1.50
Aspergillus nidulans beta-tubulin genes are unusually divergent. Gene (1987) 1.50
Paradoxical responses during the chemotherapy of tuberculosis. J Infect (1987) 1.49
Mutants of Streptococcus suis types 1 and 2 impaired in expression of muramidase-released protein and extracellular protein induce disease in newborn germfree pigs. Infect Immun (1996) 1.47
Tublin: nucleotide binding and enzymic activity. J Mol Biol (1974) 1.46
Induction of phenotypically determined resistance of Neisseria gonorrhoeae to human serum by factors in human serum. J Gen Microbiol (1981) 1.46
Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. The New York Gynecologic Oncology Group. J Clin Oncol (1993) 1.46
Proximity signal and shade avoidance differences between early and late successional trees. Nature (2001) 1.45
Patterns of neoplasia in Crohn's disease and ulcerative colitis. Cancer (1980) 1.45
A survey of the quality of information leaflets on hayfever available from general practices and community pharmacies. Clin Exp Allergy (2004) 1.44
Increase in parasuicide in Scotland. BMJ (1994) 1.43
Repeats in an extracellular protein of weakly pathogenic strains of Streptococcus suis type 2 are absent in pathogenic strains. Infect Immun (1993) 1.43
Physician performance in a prepaid health plan: results of the peer review program of the Health Insurance Plan of Greater New York. Med Care (1982) 1.43
The relation of pyrexia and nasal inflammatory response to virus levels in nasal washings of ferrets infected with influenza viruses of differing virulence. Br J Exp Pathol (1977) 1.43
Adverse reactions to carbamazepine managed by desensitisation. Lancet (1985) 1.42
Differential ability of colonial types of Neisseria gonorrhoeae to produce infection cutaneous perforated plastic chambers in guinea-pigs and rabbits. J Med Microbiol (1975) 1.42
Cerebrospinal-fluid immunoglobulins in meningitis. Lancet (1973) 1.41